Devyser Diagnostics

Devyser Diagnostics FCF Margin

The Free Cash Flow Margin of Devyser Diagnostics (DVYSR.ST) as of Oct 19, 2026 is 2.67 %. In the previous year, Free Cash Flow Margin was -57.03 % — a change of -104.69% (higher).

FCF Margin

2.67 %

YoY

-104.69%

Last updated:

Free Cash Flow Margin of Devyser Diagnostics is 2025 2.67 % . Free Cash Flow Margin of Devyser Diagnostics was 2024 -57.03 % . It decreases by -104.69% higher compared to the previous year.

The Devyser Diagnostics FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
1.99 SEK
Jan 1, 2019
8.27 SEK
Jan 1, 2020
-4.24 SEK
Jan 1, 2021
-27.04 SEK
Jan 1, 2022
-52.36 SEK
Jan 1, 2023
-60.07 SEK
Jan 1, 2024
-57.03 SEK
Jan 1, 2025
2.67 SEK
The Devyser Diagnostics FCF Margin history
YEARFCF MarginYoY
2.67 %-104.69%
-57.03 %-5.06%
-60.07 %+14.72%
-52.36 %+93.62%
-27.04 %+537.42%
-4.24 %-151.29%
8.27 %+316.16%
1.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB is a biotechnology company based in Hagersten, Sweden, operating within the healthcare sector. The company focuses on the development, manufacturing, and sale of genetic testing kits for routine diagnostics. It went public via an IPO on December 10, 2021, and currently employs 96 full-time staff. Devyser Diagnostics' products are utilized for complex DNA testing in areas such as hereditary diseases, oncology, and post-transplantation monitoring, aiding in the diagnosis of genetic conditions and guiding targeted cancer treatments. The company has developed and launched nearly 30 products for routine diagnostic use, including the Devyser Thrombophilia assay and Devyser Resolution XY, which analyzes chromosomes X and Y. These products are distributed directly to end customers or through hired distributors, with sales extending to over 45 countries. The company's website is www.devyser.com, and it is listed on the Stockholm Stock Exchange under the ticker DVYSR.ST. Devyser Diagnostics AB operates with a clear focus on providing diagnostic solutions that support medical professionals in identifying and managing genetic-related health issues through advanced testing technologies. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

Free Cash Flow Margin of Devyser Diagnostics is 2.67 % in 2025.

Free Cash Flow Margin of Devyser Diagnostics changed from -57.03 % to 2.67 %, representing a -104.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Devyser Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics